IQ-AI Provides Update on Promising Phase 1 Study of Oral Gallium Maltolate

Why we think this is neutral

This RNS provides an update on the preliminary results of a Phase 1 clinical trial for IQ-AI's subsidiary Imaging Biometrics. While the early data shows promising signs of efficacy, the announcement does not contain any of the mandatory news types required for further in-depth analysis.

Key Points

Promising preliminary data from Phase 1 study of oral Gallium Maltolate in recurrent/refractory glioblastoma patients
Early signs of efficacy, with overall survival of 32 months among evaluable subjects
No serious adverse events reported, demonstrating good tolerability of the treatment

Summary

The healthcare company reports promising preliminary data from an ongoing Phase 1 study of an oral treatment for recurrent glioblastoma patients.

IQ-AI Limited (LON: IQAI), through its subsidiary Imaging Biometrics, has announced promising preliminary results from an ongoing Phase 1 clinical trial of oral Gallium Maltolate (GaM) in patients with recurrent/refractory glioblastoma. The data shows early signs of efficacy, with an overall survival of 32 months among the 23 evaluable subjects. The company notes that further work is required, but is encouraged by the positive signals suggesting prolonged overall survival and potential anti-tumor activity with GaM.

CLINICAL TRIAL UPDATE